Amplia Says Pancreatic Cancer Trial Shows Better Results for Drug Candidate in Combination With Chemotherapy; Shares Fall 21%

MT Newswires Live2025-08-06

Amplia Therapeutics (ASX:ATX) said data from the ongoing phase 1b/2a clinical trial in the treatment of advanced pancreatic cancer with its focal adhesion kinase inhibitor narmafotinib drug candidate in combination with standard-of-care chemotherapies gemcitabine and Abraxane showed better results when compared with the results of chemotherapy alone, according to a Wednesday Australian bourse filing.

The objective response rate for the study is currently at 31%, compared with a 23% response rate for chemotherapy alone.

The adverse event profile of the narmafotinib combination is similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both types of event, rate of occurrence, and severity.

Seventeen patients are currently still enrolled in the study, with seven patients having stayed on trial for over 12 months, the filing said. The mean days on trial for evaluable patients is 202 days, compared with the 117 days reported for chemotherapy alone in the benchmark study.

An interim analysis indicates a median progression-free survival of 7.6 months, two months better than that previously reported for chemotherapy alone, per the filing.

Amplia Therapeutics' shares fell nearly 21% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2557446823?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 11:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557446823","market":"us","top_or_hot":-1,"title":"Amplia Says Pancreatic Cancer Trial Shows Better Results for Drug Candidate in Combination With Chemotherapy; Shares Fall 21%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said data from the ongoing phase 1b/2a clinical trial in the treatment of advanced pancreatic cancer with its focal adhesion kinase inhibitor narmafotinib drug candidate in combination with standard-of-care chemotherapies gemcitabine and Abraxane showed better results when compared with the results of chemotherapy alone, according to a Wednesday Australian bourse filing.</p><p>The objective response rate for the study is currently at 31%, compared with a 23% response rate for chemotherapy alone.</p><p>The adverse event profile of the narmafotinib combination is similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both types of event, rate of occurrence, and severity.</p><p>Seventeen patients are currently still enrolled in the study, with seven patients having stayed on trial for over 12 months, the filing said. The mean days on trial for evaluable patients is 202 days, compared with the 117 days reported for chemotherapy alone in the benchmark study.</p><p>An interim analysis indicates a median progression-free survival of 7.6 months, two months better than that previously reported for chemotherapy alone, per the filing.</p><p>Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares fell nearly 21% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Says Pancreatic Cancer Trial Shows Better Results for Drug Candidate in Combination With Chemotherapy; Shares Fall 21%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Says Pancreatic Cancer Trial Shows Better Results for Drug Candidate in Combination With Chemotherapy; Shares Fall 21%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-06 11:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said data from the ongoing phase 1b/2a clinical trial in the treatment of advanced pancreatic cancer with its focal adhesion kinase inhibitor narmafotinib drug candidate in combination with standard-of-care chemotherapies gemcitabine and Abraxane showed better results when compared with the results of chemotherapy alone, according to a Wednesday Australian bourse filing.</p><p>The objective response rate for the study is currently at 31%, compared with a 23% response rate for chemotherapy alone.</p><p>The adverse event profile of the narmafotinib combination is similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both types of event, rate of occurrence, and severity.</p><p>Seventeen patients are currently still enrolled in the study, with seven patients having stayed on trial for over 12 months, the filing said. The mean days on trial for evaluable patients is 202 days, compared with the 117 days reported for chemotherapy alone in the benchmark study.</p><p>An interim analysis indicates a median progression-free survival of 7.6 months, two months better than that previously reported for chemotherapy alone, per the filing.</p><p>Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares fell nearly 21% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATX.AU","symbol_name":"AMPLIA THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557446823","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557446823","pubTimestamp":1754451642,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  said data from the ongoing phase 1b/2a clinical trial in the treatment of advanced pancreatic cancer with its focal adhesion kinase inhibitor narmafotinib drug candidate in combination with standard-of-care chemotherapies gemcitabine and Abraxane showed better results when compared with the results of chemotherapy alone, according to a Wednesday Australian bourse filing.The objective response rate for the study is currently at 31%, compared with a 23% response rate for chemotherapy alone.The adverse event profile of the narmafotinib combination is similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both types of event, rate of occurrence, and severity.Seventeen patients are currently still enrolled in the study, with seven patients having stayed on trial for over 12 months, the filing said. The mean days on trial for evaluable patients is 202 days, compared with the 117 days reported for chemotherapy alone ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATX.AU":"AMPLIA THERAPEUTICS LTD","BK7067":"生物科技"},"translate_title":"Amplia表示，胰腺癌试验显示候选药物与化疗联合使用效果更好；股价下跌21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATX.AU":0.9},"content_text":"Amplia Therapeutics (ASX:ATX) said data from the ongoing phase 1b/2a clinical trial in the treatment of advanced pancreatic cancer with its focal adhesion kinase inhibitor narmafotinib drug candidate in combination with standard-of-care chemotherapies gemcitabine and Abraxane showed better results when compared with the results of chemotherapy alone, according to a Wednesday Australian bourse filing.The objective response rate for the study is currently at 31%, compared with a 23% response rate for chemotherapy alone.The adverse event profile of the narmafotinib combination is similar to adverse events previously reported for the chemotherapy combination of gemcitabine and Abraxane, in both types of event, rate of occurrence, and severity.Seventeen patients are currently still enrolled in the study, with seven patients having stayed on trial for over 12 months, the filing said. The mean days on trial for evaluable patients is 202 days, compared with the 117 days reported for chemotherapy alone in the benchmark study.An interim analysis indicates a median progression-free survival of 7.6 months, two months better than that previously reported for chemotherapy alone, per the filing.Amplia Therapeutics' shares fell nearly 21% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2557446823","isCrawlerRequest":true}